FDMT 241220 7.50C (FDMT241220C7500) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

FDMT241220C7500

Watchlist

0.30
-0.10-25.00%

15min DelayClose Dec 10 16:00 ET

0.35High0.25Low

Intraday

5D
Daily

News

We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
Simply Wall StNov 27 06:17 ET
4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now
Yahoo FinanceNov 26 06:51 ET
4D Molecular Initiated by Morgan Stanley at Underweight
Seeking AlphaNov 21 13:58 ET
Morgan Stanley Initiates 4D Molecular Therapeutics(FDMT.US) With Sell Rating, Announces Target Price $8
Moomoo NewsNov 21 05:31 ET · Ratings
4D Molecular Therapeutics' Positive Q3 and Strategic Advances
TipRanksNov 15 22:53 ET
Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $39
Moomoo NewsNov 14 17:32 ET · Ratings

Comments

北美深蓝

Jul 23 20:31

$4D Molecular Therapeutics (FDMT.US)$
🌈 静待股价回落，长线标的，观察仓开仓目标价14.85
⭕ Regulation FD Disclosure.
On July 23, 2024, 4D Molecular Therapeutics, Inc. (the “Company”) reported that interim longest available follow up data from the Phase 1 Dose Expansion cohort, Phase 2 Dose Expansion cohort, and Phase 2 Population Extension cohort from its Phase 1/2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration are expected to be presented at a medical conference in Septemb...